For information only:
According to an article on the UCB website, Neupro will be available in the USA in the near future.
* Neupro (rotigotine transdermal system) is approved to treat the signs and symptoms of early and advanced stage idiopathic Parkinson’s disease and moderate-to-severe primary restless legs syndrome
* Neupro is a dopamine agonist patch that provides continuous drug delivery for patients with PD and RLS
* Over 100,000 patients have been treated with Neupro® worldwide and seven pivotal trials demonstrate efficacy, safety and tolerability for PD and RLS1
* Neupro® will be available in U.S. retail pharmacies in July 2012